Molecure S.A. (FRA:1B1)

Market Cap	29.39M -20.9%
Revenue (ttm)	1.55M +123.3%
Net Income	-3.72M
EPS	-0.18
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	1.356
Previous Close	1.334
Day's Range	1.356 - 1.356
52-Week Range	1.150 - 2.020
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 30, 2026

About Molecure

Molecure S.A., a biotechnology company, engages in discovering, developing, and commercializing therapeutics for neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed Phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH. It also develops OATD-02, an arginase 1 and arginase 2, which is in Phase I clinical trial for the treatment of cancer; USP7, USP21, and YKL-4...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 71
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1B1

Financial Performance

In 2025, Molecure's revenue was 6.52 million, an increase of 123.34% compared to the previous year's 2.92 million. Losses were -15.69 million, -49.86% less than in 2024.

Financial numbers in PLN

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error